Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Metyrapone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44364   clinical trials with a EudraCT protocol, of which   7388   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: Metyrapone. Displaying page 1 of 1.
    EudraCT Number: 2007-000137-19 Sponsor Protocol Number: Start Date*: 2007-08-07
    Sponsor Name:Leiden University Medical Center
    Full Title: Metyrapone as additive treatment in patients with major depression
    Medical condition: unipolar depressive episode without psychotic features according to DSM-IV-TR
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027515 Metyrapone challenge test LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002063-26 Sponsor Protocol Number: METYX01 Start Date*: 2013-09-08
    Sponsor Name:S.C.D.U. MEDICINA INTERNA 1 Ospedale San Luigi Orbassano
    Full Title: A prospective open-label Phase 2 study of METYRAPONE as a preoperative treatment in patients with ACTH-independent Cushing’s syndrome due to adrenal adenoma.
    Medical condition: Cushing's syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015165-31 Sponsor Protocol Number: EME-08/43/39 Start Date*: 2010-07-16
    Sponsor Name:Northumberland, Tyne and Wear NHS Foundation Trust
    Full Title: Antiglucocorticoid augmentation of antiDepressants in Depression: a double-blind, randomised, placebo-controlled, parallel-group trial
    Medical condition: depression
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2022-000161-40 Sponsor Protocol Number: AdrenalClock Start Date*: 2022-07-18
    Sponsor Name:Medical University of Vienna, Division of Endocrinology
    Full Title: Investigating cardiometabolic risk factors and changes in chronobiology patterns in patients with autonomous adrenal cortisol secretion
    Medical condition: Autonomous cortisol secretion in patients with adrenal adenoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000162-22 Sponsor Protocol Number: 112025-002 Start Date*: 2015-05-04
    Sponsor Name:Laboratoire HRA Pharma
    Full Title: Prospective, single arm, open-label, multicenter, international study to assess the effects of metyrapone in patients with endogenous Cushing’s syndrome during a 12-week treatment period followed b...
    Medical condition: Treatment of Cushing’s syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10011652 Cushing's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) BE (Completed) ES (Completed) HU (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2019-002008-41 Sponsor Protocol Number: GR-MET-19 Start Date*: 2019-09-05
    Sponsor Name:AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI
    Full Title: Effect of metyrapone on cardiovascular risk factors in patients with adrenal incidentalomas and subclinical/mild Cushing's syndrome
    Medical condition: patients with adrenal incidentalomas and subclinical/mild Cushing’s syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10011652 Cushing's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-004111-22 Sponsor Protocol Number: CSOM230B2305 Start Date*: 2007-01-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recu...
    Medical condition: Cushing’s disease is rare disease that is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma. The elevated ACTH secreted by these tumors stimulates the adrenal glands to pr...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011651 Cushing's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) BE (Completed) IT (Completed) FI (Completed) FR (Completed) DE (Completed) PT (Completed) GR (Completed) GB (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-022403-22 Sponsor Protocol Number: CLCI699C2201 Start Date*: 2011-07-04
    Sponsor Name:NOVARTIS FARMA
    Full Title: A proof-of concept, open-label, forced titration, multicenter study to assess the safety/tolerability and efficacy of 10-weeks treatment of LCI699 in patients with Cushing’s disease
    Medical condition: Cushing's disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10014698 - Endocrine disorders 10011652 Cushing's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004647-20 Sponsor Protocol Number: COR-2017-OLE Start Date*: 2018-11-13
    Sponsor Name:Cortendo AB
    Full Title: An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome
    Medical condition: Endogenous Cushing´s syndrome (CS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10011657 Cushings syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BG (Completed) ES (Ongoing) IT (Completed) NL (Completed) GR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-001219-35 Sponsor Protocol Number: COR-2017-01 Start Date*: 2018-01-22
    Sponsor Name:Cortendo AB
    Full Title: A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open-label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenou...
    Medical condition: Endogenous Cushing´s syndrome (CS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10011657 Cushings syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) BG (Completed) HU (Completed) PL (Completed) NL (Completed) DK (Prematurely Ended) GR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2009-011128-70 Sponsor Protocol Number: CSOM230G2304 Start Date*: 2011-08-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, multicentre, phase III study to evaluate the efficacy and safety of pasireotide LAR in patients with Cushing’s disease
    Medical condition: Cushing's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004860 10011651 Cushing's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) NL (Completed) BE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-024165-44 Sponsor Protocol Number: CSOM230B2406 Start Date*: 2011-08-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, multi-center, expanded access study of pasireotide s.c. in patients with Cushing’s disease (Seascape)
    Medical condition: Cushing’s disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10011651 Cushing's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GR (Prematurely Ended) ES (Completed) CZ (Completed) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Oct 31 00:49:08 CET 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA